VERV241220P5000
- 0.20
- 0.000.00%
Verve Therapeutics Newsroom
RBC Capital Maintains Verve Therapeutics(VERV.US) With Buy Rating, Cuts Target Price to $17
CCORF Maintains Verve Therapeutics(VERV.US) With Buy Rating, Raises Target Price to $32
J.P. Morgan Maintains Verve Therapeutics(VERV.US) With Hold Rating, Cuts Target Price to $23
Verve Therapeutics Is Maintained at Outperform by RBC Capital
Verve Therapeutics Analyst Ratings
A Quick Look at Today's Ratings for Verve Therapeutics(VERV.US), With a Forecast Between $14 to $23
J.P. Morgan Keeps Their Hold Rating on Verve Therapeutics (VERV)
Verve Therapeutics Price Target Cut to $29.00/Share From $30.00 by Canaccord Genuity
HC Wainwright & Co. Reiterates Buy on Verve Therapeutics, Maintains $15 Price Target
RBC Capital Maintains Outperform on Verve Therapeutics, Lowers Price Target to $20
Buy Rating Affirmed for Verve Therapeutics Amidst Clinical Progress and Strong Financials
RBC Capital Remains a Buy on Verve Therapeutics (VERV)
Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), 4D Molecular Therapeutics (FDMT) and Carisma Therapeutics (CARM)
RBC Cuts Price Target on Verve Therapeutics to $25 From $35, Keeps Outperform, Speculative Risk
Buy Rating Affirmed for Verve Therapeutics Amidst Promising Trials and Strong Financials
HC Wainwright & Co. Reiterates Buy on Verve Therapeutics, Maintains $15 Price Target
Verve Therapeutics Analyst Ratings
RBC Capital Keeps Their Buy Rating on Verve Therapeutics (VERV)
Buy Rating for Verve Therapeutics: Financial Stability and Promising Clinical Trials Underpin Growth Potential
Buy Rating Affirmed for Verve Therapeutics Amid Progress and Promising Pipeline